Supernus Prescription drugs to Announce Second Quarter 2022
Pharmaceuticals

Supernus Prescription drugs to Announce Second Quarter 2022

ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) — Supernus Prescription drugs, Inc. (Nasdaq: SUPN), a biopharmaceutical firm targeted on creating and commercializing merchandise for the therapy of central nervous system (CNS) illnesses, right this moment introduced that the Firm expects to report monetary and enterprise outcomes for the second quarter of 2022 after the market closes on Thursday, August 4, 2022.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a convention name to current the second quarter 2022 monetary and enterprise outcomes on Thursday, August 4, 2022 at 4:30 p.m. ET. Following administration’s ready remarks and dialogue of enterprise outcomes, the decision will probably be open for questions.

A reside webcast will probably be accessible within the Occasions & Presentation part of the Firm’s Investor Relations web site www.supernus.com/buyers.

Members might also pre-register any time earlier than the decision right here. As soon as registration is accomplished, members will probably be offered a dial-in quantity with a personalised convention code to entry the decision. Please dial in quarter-hour previous to the beginning time.

Following the reside name, a replay will probably be out there on the Firm’s Investor Relations web site www.supernus.com/buyers. The webcast will probably be out there on the Firm’s web site for 60 days following the reside name.

About Supernus Prescription drugs, Inc.

Supernus Prescription drugs is a biopharmaceutical firm targeted on creating and commercializing merchandise for the therapy of central nervous system (CNS) illnesses.

Our various neuroscience portfolio contains permitted therapies for epilepsy, migraine, ADHD, hypomobility in Parkinson’s illness (PD), cervical dystonia, continual sialorrhea, dyskinesia in PD sufferers receiving levodopa-based remedy, and drug-induced extrapyramidal reactions in grownup sufferers. We’re creating a broad vary of novel CNS product candidates together with new potential therapies for hypomobility in PD, epilepsy, melancholy, and different CNS problems.

For extra info, please go to www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEO
Tim Dec, Senior Vice President and CFO
Supernus Prescription drugs, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Workplace: (443) 213-0505
Cell: (443) 377-4767
E-mail: peter.vozzo@westwicke.com